Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Pharma Insider To Payer: Witty To Lead United's Optum

Executive Summary

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

Advertisement

Related Content

Appointments: Rice Goes To CVS, A New CFO At J&J And Changes at Merck & Co, Alder, Hansa, OncoMed, Modus Therapeutics, Astellas Americas And Others
Praluent Pricing: Collaboration With ICER Sets A New Standard
New UK Pathway To Cut Access Times For Breakthrough Products By Up To Four Years
Industry Sounds Somewhat Muted Drug Pricing Alarm
GSK’s New CEO Designate Walmsley Fortifies Volume Growth Strategy
GSK Reveals Big Changes As 2015 Growth Prospects Fizzle
GSK’s Witty Speaks Further On M&A, Pricing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel